Skip to main content
Top
Published in: AIDS and Behavior 2/2013

01-10-2013 | Original Paper

Cost Analysis of Enhancing Linkages to HIV Care Following Jail: A Cost-Effective Intervention

Authors: Anne C. Spaulding, Steven D. Pinkerton, Hillary Superak, Marc J. Cunningham, Stephen Resch, Alison O. Jordan, Zhou Yang

Published in: AIDS and Behavior | Special Issue 2/2013

Login to get access

Abstract

We are not aware of published cost-effectiveness studies addressing community transitional programs for HIV-infected jail detainees. To address this gap, data from 9 sites of EnhanceLink, a project that enrolled HIV-infected releasees from jails across the US, were examined. Figures on the number of clients served, cost of linkage services, number of linkages and 6-month sustained linkages to community HIV care, and number of clients achieving viral suppression were assessed for subjects released in the first quarter of 2010 (n = 543). The cost analysis included all costs that participating service agencies incurred. A cost-effectiveness analysis was conducted to estimate the new HIV cases averted by EnhanceLink and the cost per quality-adjusted life year saved by the program. The mean cost per linked client was $4,219; the mean cost per 6-month sustained linkage was $4,670; and the mean cost per client achieving viral suppression was $8,432. Compared to standard care, the cost per additional quality-adjusted life year saved was $72,285, suggesting that the EnhanceLink interventions were cost-effective from the societal perspective.
Literature
1.
go back to reference Spaulding AC, Seals RM, Page MJ, Brzozowski AK, Rhodes W, Hammett TM. HIV/AIDS among inmates of, and releasees from, US correctional facilities, 2006 declining share of epidemic but persistent public health opportunity. PLoS One. 2009;4(11):e7558. doi:10.1371/journal.pone.0007558.PubMedCrossRef Spaulding AC, Seals RM, Page MJ, Brzozowski AK, Rhodes W, Hammett TM. HIV/AIDS among inmates of, and releasees from, US correctional facilities, 2006 declining share of epidemic but persistent public health opportunity. PLoS One. 2009;4(11):e7558. doi:10.​1371/​journal.​pone.​0007558.PubMedCrossRef
2.
go back to reference Westergaard RP, Kirk GD, Richesson DR, Galai N, Mehta SH. Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy. Clin Infect Dis. 2011;53(7):725–31.PubMedCrossRef Westergaard RP, Kirk GD, Richesson DR, Galai N, Mehta SH. Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy. Clin Infect Dis. 2011;53(7):725–31.PubMedCrossRef
4.
go back to reference Shrestha RK, Sansom SL, Richardson-Moore A, et al. Costs of voluntary rapid HIV testing and counseling in jails in 4 states advancing HIV prevention demonstration project 2003–2006. Sex Transm Dis. 2009;36(Suppl 2):S5–8.PubMed Shrestha RK, Sansom SL, Richardson-Moore A, et al. Costs of voluntary rapid HIV testing and counseling in jails in 4 states advancing HIV prevention demonstration project 2003–2006. Sex Transm Dis. 2009;36(Suppl 2):S5–8.PubMed
5.
go back to reference Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr: JAIDS. 2005;39(4):446–53.PubMedCrossRef Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr: JAIDS. 2005;39(4):446–53.PubMedCrossRef
6.
go back to reference Holtgrave DR, Hall HI, Rhodes PH, Wolitski RJ. Updated annual HIV transmission rates in the United States, 1977–2006 (Letter to the editor). J Acquir Immune Defic Syndr. 2009;50:236–8.PubMedCrossRef Holtgrave DR, Hall HI, Rhodes PH, Wolitski RJ. Updated annual HIV transmission rates in the United States, 1977–2006 (Letter to the editor). J Acquir Immune Defic Syndr. 2009;50:236–8.PubMedCrossRef
7.
go back to reference Draine J, Ahuja D, Altice FL, et al. Strategies to enhance linkages between care for HIV/AIDS in jail and community settings. AIDS Care. 2011;23(3):366–77.PubMedCrossRef Draine J, Ahuja D, Altice FL, et al. Strategies to enhance linkages between care for HIV/AIDS in jail and community settings. AIDS Care. 2011;23(3):366–77.PubMedCrossRef
8.
go back to reference Pinkerton S. HIV Transmission rate modeling: a primer, review, and extension. AIDS Behav. 2012;16(4):791–6.PubMedCrossRef Pinkerton S. HIV Transmission rate modeling: a primer, review, and extension. AIDS Behav. 2012;16(4):791–6.PubMedCrossRef
9.
go back to reference Centers for Disease Control and Prevention. HIV surveillance—United States, 1981–2008. MMWR. 2011;60:689–93. Centers for Disease Control and Prevention. HIV surveillance—United States, 1981–2008. MMWR. 2011;60:689–93.
10.
go back to reference Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006–2009. PLoS One. 2011;6(8):e17502.PubMedCrossRef Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006–2009. PLoS One. 2011;6(8):e17502.PubMedCrossRef
11.
go back to reference Gardner LI, Metsch LR, Anderson-Mahoney P, et al. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS. 2005;19(4):423–31.PubMedCrossRef Gardner LI, Metsch LR, Anderson-Mahoney P, et al. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS. 2005;19(4):423–31.PubMedCrossRef
12.
go back to reference Hutchinson AB, Farnham PG, Dean HD, Ekwueme DU, del Rio C, Kamimoto L. The economic burden of HIV in the US in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. JAIDS. 2006;43(4):451–7.PubMedCrossRef Hutchinson AB, Farnham PG, Dean HD, Ekwueme DU, del Rio C, Kamimoto L. The economic burden of HIV in the US in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. JAIDS. 2006;43(4):451–7.PubMedCrossRef
13.
go back to reference Gebo KA, Fleishman JA, Conviser R, et al. Contemporary costs of HIV healthcare in the HAART era. AIDS. 2010;24(17):2705–15.PubMedCrossRef Gebo KA, Fleishman JA, Conviser R, et al. Contemporary costs of HIV healthcare in the HAART era. AIDS. 2010;24(17):2705–15.PubMedCrossRef
14.
go back to reference Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44(11):990–7.PubMedCrossRef Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44(11):990–7.PubMedCrossRef
15.
go back to reference Farnham PG, Sansom SL, Hutchinson AB. How much should we pay for a new HIV diagnosis? A mathematical model of HIV screening in US clinical settings. Méd Decis Mak. 2012;32(3):459–69.CrossRef Farnham PG, Sansom SL, Hutchinson AB. How much should we pay for a new HIV diagnosis? A mathematical model of HIV screening in US clinical settings. Méd Decis Mak. 2012;32(3):459–69.CrossRef
16.
go back to reference Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.PubMedCrossRef Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.PubMedCrossRef
17.
go back to reference Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342(13):921–9.PubMedCrossRef Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342(13):921–9.PubMedCrossRef
21.
go back to reference Cohen SM, van Handel MM, Branson BM, et al. Vital Signs: HIV prevention through care and treatment—United States MMWR. 2011;60(47):1618–23. Cohen SM, van Handel MM, Branson BM, et al. Vital Signs: HIV prevention through care and treatment—United States MMWR. 2011;60(47):1618–23.
22.
go back to reference Pinkerton SD. How many sexually-acquired HIV infections in the USA are due to acute phase HIV transmission? AIDS. 2007;21:1625–29. Pinkerton SD. How many sexually-acquired HIV infections in the USA are due to acute phase HIV transmission? AIDS. 2007;21:1625–29.
23.
go back to reference Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they infected with the virus in the USA. AIDS. Jun 26 2006;20(10):1447–50. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they infected with the virus in the USA. AIDS. Jun 26 2006;20(10):1447–50.
Metadata
Title
Cost Analysis of Enhancing Linkages to HIV Care Following Jail: A Cost-Effective Intervention
Authors
Anne C. Spaulding
Steven D. Pinkerton
Hillary Superak
Marc J. Cunningham
Stephen Resch
Alison O. Jordan
Zhou Yang
Publication date
01-10-2013
Publisher
Springer US
Published in
AIDS and Behavior / Issue Special Issue 2/2013
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-012-0353-4

Other articles of this Special Issue 2/2013

AIDS and Behavior 2/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.